

## BIBLIOGRAFIA

- 1) Bagley, S., Barnes, J., Blunt, B., Foreman, J., Hadland, S., Mayen, S., McMahan, R., Punch, L. J., & Taichman, D. (2024). Treating Opioid Use Disorder in General Practice - Diagnosis, Harm Reduction, and Medications. *The New England journal of medicine*, 390(2), e3. <https://doi.org/10.1056/NEJMp2310171>
- 2) Volkow, N. D., & Blanco, C. (2023). Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. *World psychiatry : official journal of the World Psychiatric Association (WPA)*, 22(2), 203–229. <https://doi.org/10.1002/wps.21073>
- 3) Aspinall, E. J., Nambiar, D., Goldberg, D. J., Hickman, M., Weir, A., Van Velzen, E., Palmateer, N., Doyle, J. S., Hellard, M. E., & Hutchinson, S. J. (2014). Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. *International journal of epidemiology*, 43(1), 235–248. <https://doi.org/10.1093/ije/dyt243>
- 4) Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., Hope, V., Hutchinson, S., Maher, L., Palmateer, N., Taylor, A., Bruneau, J., & Hickman, M. (2017). Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. *The Cochrane database of systematic reviews*, 9(9), CD012021. <https://doi.org/10.1002/14651858.CD012021.pub2>
- 5) Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. *J Urban Health*. 2011 Dec;88(6):1020-30. doi: 10.1007/s11524-011-9600-7. PMID: 21773877; PMCID: PMC3232410.
- 6) Ellis, J. D., Dunn, K. E., & Huhn, A. S. (2024). Harm Reduction for Opioid Use Disorder: Strategies and Outcome Metrics. *The American journal of psychiatry*, 181(5), 372–380. <https://doi.org/10.1176/appi.ajp.20230918>
- 7) Lin, L. A., Bonar, E. E., & Coughlin, L. N. (2024). Toward a Harm Reduction Approach to Cannabis Use Disorder. *The American journal of psychiatry*, 181(2), 98–99. <https://doi.org/10.1176/appi.ajp.20230381>
- 8) Paquette, C. E., Daughters, S. B., & Witkiewitz, K. (2022). Expanding the continuum of substance use disorder treatment: Nonabstinence approaches. *Clinical psychology review*, 91, 102110. <https://doi.org/10.1016/j.cpr.2021.102110>
- 9) Hagan H, Des Jarlais DC: HIV and HCV infection among injecting drug users. *Mt Sinai J Med* 2000; 67:423–428

- 10) Galea, S., & Vlahov, D. (2002). Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. *Public health reports (Washington, D.C. : 1974)*, 117 Suppl 1(Suppl 1), S135–S145.
- 11) McNeil, R., Jauffret-Roustide, M., & Hansen, H. (2022). Reducing Drug-Related Harms and Promoting Health Justice Worldwide During and After COVID-19: An *AJPH* Supplement. *American journal of public health*, 112(S2), S95–S98.  
<https://doi.org/10.2105/AJPH.2022.306804>
- 12) Hansen, H., Jordan, A., Plough, A., Alegria, M., Cunningham, C., & Ostrovsky, A. (2022). Lessons for the Opioid Crisis-Integrating Social Determinants of Health Into Clinical Care. *American journal of public health*, 112(S2), S109–S111.  
<https://doi.org/10.2105/AJPH.2021.306651>
- 13) Kirkbride, J. B., Anglin, D. M., Colman, I., Dykxhoorn, J., Jones, P. B., Patalay, P., Pitman, A., Sonesson, E., Steare, T., Wright, T., & Griffiths, S. L. (2024). The social determinants of mental health and disorder: evidence, prevention and recommendations. *World psychiatry : official journal of the World Psychiatric Association (WPA)*, 23(1), 58–90. <https://doi.org/10.1002/wps.21160>
- 14) Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. *Addiction* 2011; 106: 1978–88.
- 15) Degenhardt, L., Grebely, J., Stone, J., Hickman, M., Vickerman, P., Marshall, B. D. L., Bruneau, J., Altice, F. L., Henderson, G., Rahimi-Movaghar, A., & Larney, S. (2019). Global patterns of opioid use and dependence: harms to populations, interventions, and future action. *Lancet (London, England)*, 394(10208), 1560–1579.  
[https://doi.org/10.1016/S0140-6736\(19\)32229-9](https://doi.org/10.1016/S0140-6736(19)32229-9)
- 16) Motie, I., Carretta, H. J., & Beitsch, L. M. (2020). Needling Policy Makers and Sharpening the Debate: Do Syringe Exchange Programs Improve Health at the Population Level?. *Journal of public health management and practice : JPHMP*, 26(3), 222–226. <https://doi.org/10.1097/PHH.0000000000001152>
- 17) Ray, B. R., Humphrey, J. L., Patel, S. V., Akiba, C. F., Bluthenthal, R. N., Tookes, H., LaKosky, P. A., Wenger, L. D., Kral, A. H., & Lambdin, B. H. (2024). Comparing harm reduction and overdose response services between community-based and public health department syringe service programmes using a national cross-sectional survey. *Lancet regional health. Americas*, 34, 100757.  
<https://doi.org/10.1016/j.lana.2024.100757>
- 18) Peacock, A., Bruno, R., Gisev, N., Degenhardt, L., Hall, W., Sedefov, R., White, J., Thomas, K. V., Farrell, M., & Griffiths, P. (2019). New psychoactive substances: challenges for drug surveillance, control, and public health responses. *Lancet*

- (London, England), 394(10209), 1668–1684. [https://doi.org/10.1016/S0140-6736\(19\)32231-7](https://doi.org/10.1016/S0140-6736(19)32231-7)
- 19) F. Scheibin, J. S. G. Wells, S. Henriques & M. C. Van Hout (2020) The impacts and service responses to injecting cathinones and novel opioids amongst marginalized drug using populations – a scoping review, *Journal of Substance Use*, 25:3, 238-245, DOI:10.1080/14659891.2019.1698671
  - 20) Maghsoudi, N., Tanguay, J., Scarfone, K., Rammohan, I., Ziegler, C., Werb, D., & Scheim, A. I. (2022). Drug checking services for people who use drugs: a systematic review. *Addiction (Abingdon, England)*, 117(3), 532–544. <https://doi.org/10.1111/add.15734>
  - 21) Pidd, K., Roche, A., Cameron, J., Lee, N., Jenner, L., & Duraisingam, V. (2018). Workplace alcohol harm reduction intervention in Australia: Cluster non-randomised controlled trial. *Drug and alcohol review*, 37(4), 502–513. <https://doi.org/10.1111/dar.12660>
  - 22) Rosen, J., Zelnick, J. R., Zoeckler, J., & Landsbergis, P. (2021). Introduction to the Special Issue: Opioids and the Workplace - Risk Factors and Solutions. *New solutions : a journal of environmental and occupational health policy : NS*, 31(3), 201–209. <https://doi.org/10.1177/10482911211048438>
  - 23) Komalasari, R., Wilson, S., & Haw, S. (2021). A systematic review of qualitative evidence on barriers to and facilitators of the implementation of opioid agonist treatment (OAT) programmes in prisons. *The International journal on drug policy*, 87, 102978. <https://doi.org/10.1016/j.drugpo.2020.102978>
  - 24) Jakubowski, A., Fowler, S., & Fox, A. D. (2023). Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature. *Addiction science & clinical practice*, 18(1), 40. <https://doi.org/10.1186/s13722-023-00394-x>
  - 25) Childs, E., Biello, K. B., Valente, P. K., Salhaney, P., Biancarelli, D. L., Olson, J., Earlywine, J. J., Marshall, B. D. L., & Bazzi, A. R. (2021). Implementing harm reduction in non-urban communities affected by opioids and polysubstance use: A qualitative study exploring challenges and mitigating strategies. *The International journal on drug policy*, 90, 103080. <https://doi.org/10.1016/j.drugpo.2020.103080>
  - 26) Strike, C., & Miskovic, M. (2018). Scoping out the literature on mobile needle and syringe programs-review of service delivery and client characteristics, operation, utilization, referrals, and impact. *Harm reduction journal*, 15(1), 6. <https://doi.org/10.1186/s12954-018-0212-3>
  - 27) Cox, S., Moss, A. C., & Ritter, A. (2020). Editorial for special issue: Vulnerable groups: Addiction research, policy and practice. *Addictive behaviors*, 104, 106266. <https://doi.org/10.1016/j.addbeh.2019.106266>

- 28) Pates, R. and Riley, D. (2009), Interventions for amphetamine misuse, Wiley-Blackwell, Oxford.
- 29) Allott, K., & Redman, J. (2006). Patterns of use and harm reduction practices of ecstasy users in Australia. *Drug and alcohol dependence*, 82(2), 168–176.  
<https://doi.org/10.1016/j.drugalcdep.2005.09.009>
- 30) Vera, B. D. V., Carmona-Marquez, J., Vidal-Giné, C., & Fernández-Calderón, F. (2021). Harm Reduction Strategies and Drug-Related Negative Consequences in the Dance Music Scene: The Moderating Role of Polysubstance Use. *Substance use & misuse*, 56(6), 777–781. <https://doi.org/10.1080/10826084.2021.1892144>
- 31) McCrae K, Tobias S, Tupper K, Arredondo J, Henry B, Mema S, et al. Drug checking services at music festivals and events in a Canadian setting. *Drug Alcohol Depend.* 2019;205(107589):107589. <https://doi.org/10.1016/j.drugalcdep.2019.107589>.
- 32) Hondebrink L, Nugteren-van Lonkhuyzen JJ, Hunault CC, van den Berg J, van der Gouwe D, van Riel AJHP. New psychoactive substances (NPS) in the Netherlands: occurrence in forensic drug samples, consumer drug samples and poisons center exposures between 2013 and 2017. *Addiction.* 2020;115(4):716–25. <https://doi.org/10.1111/add.14868>.
- 33) Barratt MJ, Bruno R, Ezard N, Ritter A. Pill testing or drug checking in Australia: acceptability of service design features. *Drug Alcohol Rev.* 2018;37(2):226–36. <https://doi.org/10.1111/dar.12576>.
- 34) Maghsoudi, N., Tanguay, J., Scarfone, K., Rammohan, I., Ziegler, C., Werb, D., & Scheim, A. I. (2022). Drug checking services for people who use drugs: a systematic review. *Addiction (Abingdon, England)*, 117(3), 532–544.  
<https://doi.org/10.1111/add.15734>
- 35) Klaire, S., Janssen, R. M., Olson, K., Bridgeman, J., Korol, E. E., Chu, T., Ghafari, C., Sabeti, S., Buxton, J. A., & Lysyshyn, M. (2022). Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada. *The International journal on drug policy*, 106, 103741. <https://doi.org/10.1016/j.drugpo.2022.103741>
- 36) Fisher H. L. (2024). The public mental health revolution must privilege lived experience voices and create alliances with affected communities. *World psychiatry : official journal of the World Psychiatric Association (WPA)*, 23(1), 2–3.  
<https://doi.org/10.1002/wps.21149>
- 37) Lennox, R., Martin, L., Brimner, C., & O'Shea, T. (2021). Hospital policy as a harm reduction intervention for people who use drugs. *The International journal on drug policy*, 97, 103324. <https://doi.org/10.1016/j.drugpo.2021.103324>